替格瑞洛联合美托洛尔治疗急性冠脉综合征的临床护理疗效观察
|
摘要
目的观察替格瑞洛联合美托洛尔治疗急性冠状动脉(冠脉)综合征的临床疗效和护理效果。方法 88例急性冠脉综合征患者,随机将其分为对照组和观察组,每组44例。对照组患者行替格瑞洛治疗,观察组患者在对照组的基础上增加美托洛尔治疗。观察并对比两组治疗前后C反应蛋白(CRP)、肌酸激酶-同工酶(CK-MB)、肌钙蛋白T(cTnT)、胸痛总积分水平及心律失常的发生情况,观察并对比两组患者治疗效果。结果观察组患者的临床治疗总有效率为95.45%,高于对照组的81.82%,差异具有统计学意义(χ~2=4.0615, P=0.0438<0.05)。治疗前,两组患者CRP水平、CK-MB、cTnT、胸痛总积分及心律失常发生率比较,差异无统计学意义(P>0.05);治疗后,两组患者CRP水平、CK-MB水平、cTnT水平及胸痛总积分、心律失常发生率均低于治疗前,且观察组低于对照组,差异具有统计学意义(P<0.05)。结论对急性冠脉综合征患者应用替格瑞洛联合美托洛尔治疗,相较于单一替格瑞洛治疗疗效更为显著,可有效抑制患者心肌收缩,降低猝死率,值得临床推广。
Objective To observe the clinical efficacy and nursing effect of ticagrelor combined with metoprolol in the treatment of acute coronary syndrome. Methods A total of 88 patients with acute coronary syndrome were randomly divided into control group and observation group, with 44 cases in each group. The control group was treated with ticagrelor, and the observation group was treated with metoprolol on the basis of the control group. Observation and comparison were made on C-reactive protein(CRP), creatine kinase-MB(CK-MB), troponin T(cTnT), total score of chest pain and occurrence of arrhythmia before and after treatment and treatment effect between the two groups. Results The observation group had higher total effective rate of clinical treatment as 95.45% than 81.82% in the control group, and the difference was statistically significant(χ~2=4.0615, P=0.0438<0.05). Before treatment, both groups had no statistically significant difference in CRP,CK-MB,cTnT, total score of chest pain and incidence of arrhythmia(P>0.05). After treatment, both groups had lower CRP,CK-MB,cTnT,total score of chest pain and incidence of arrhythmia than those before treatment,and the observation group was lower than the control group. Their difference was statistically significant(P<0.05).Conclusion Ticagrelor combined with metoprolol is more effective than single ticagrelor in the treatment of acute coronary syndrome,and it can effectively inhibit myocardial contraction and reduce sudden death rate.It is worthy of clinical promotion.
Objective To observe the clinical efficacy and nursing effect of ticagrelor combined with metoprolol in the treatment of acute coronary syndrome. Methods A total of 88 patients with acute coronary syndrome were randomly divided into control group and observation group, with 44 cases in each group. The control group was treated with ticagrelor, and the observation group was treated with metoprolol on the basis of the control group. Observation and comparison were made on C-reactive protein(CRP), creatine kinase-MB(CK-MB), troponin T(cTnT), total score of chest pain and occurrence of arrhythmia before and after treatment and treatment effect between the two groups. Results The observation group had higher total effective rate of clinical treatment as 95.45% than 81.82% in the control group, and the difference was statistically significant(χ~2=4.0615, P=0.0438<0.05). Before treatment, both groups had no statistically significant difference in CRP,CK-MB,cTnT, total score of chest pain and incidence of arrhythmia(P>0.05). After treatment, both groups had lower CRP,CK-MB,cTnT,total score of chest pain and incidence of arrhythmia than those before treatment,and the observation group was lower than the control group. Their difference was statistically significant(P<0.05).Conclusion Ticagrelor combined with metoprolol is more effective than single ticagrelor in the treatment of acute coronary syndrome,and it can effectively inhibit myocardial contraction and reduce sudden death rate.It is worthy of clinical promotion.
引文
[1]佟秋艳,郭海平.替格瑞洛在老年急性冠状动脉综合征患者经皮冠状动脉介入术后的安全性观察.山西医药杂志, 2018,47(24):2978-2979.
[2]崔勤,周少名,杨加东,等.替格瑞洛对经皮冠状动脉介入治疗术后急性冠脉综合征患者的疗效观察.锦州医科大学学报,2018(6):25-27.
[3]马登峰,裴志强,李炳蔚,等.急性冠脉综合征经皮冠状动脉介入术后替格瑞洛单药治疗的临床观察.中华医学杂志, 2018,98(43):3542-3544.
[4]乔永洁,谢宗雪.早期静脉应用美托洛尔对急性冠脉综合征患者心肌损伤的影响.实用临床医药杂志, 2016, 20(11):11-14.
[5]葛国栋.美托洛尔静脉注射治疗急性冠脉综合征合并室性心律失常41例临床分析.临床医学研究与实践, 2016, 1(11):31.
[6]陶卫国,宋飞月,张高喜,等.美托洛尔对急性心肌梗死患者心功能和心率的影响.深圳中西医结合杂志, 2018, 28(7):160-161.
[7]王莉,陈静,贾艳梅,等.替格瑞洛联合阿司匹林治疗急性冠脉综合征的临床疗效及护理观察.中国医药导刊, 2014(8):1243-1244.
[8]孙美瑜.阿司匹林联合替格瑞洛治疗急性冠状动脉综合征的临床疗效观察.中国医药指南, 2018(8):32.
[9]劳国华,陈晓燕,黄子通.替格瑞洛联合阿司匹林治疗急性冠脉综合征的临床观察.岭南心血管病杂志, 2014, 20(3):317-318.
[10]潘迪,黄菲.替格瑞洛联合阿司匹林治疗急性冠脉综合征疗效观察.中国实用医药, 2016, 11(29):143-145.
[11]周金和.替格瑞洛联合波立维治疗急性冠状动脉综合征的临床疗效研究.川北医学院学报, 2018, 33(6):923-925.
[2]崔勤,周少名,杨加东,等.替格瑞洛对经皮冠状动脉介入治疗术后急性冠脉综合征患者的疗效观察.锦州医科大学学报,2018(6):25-27.
[3]马登峰,裴志强,李炳蔚,等.急性冠脉综合征经皮冠状动脉介入术后替格瑞洛单药治疗的临床观察.中华医学杂志, 2018,98(43):3542-3544.
[4]乔永洁,谢宗雪.早期静脉应用美托洛尔对急性冠脉综合征患者心肌损伤的影响.实用临床医药杂志, 2016, 20(11):11-14.
[5]葛国栋.美托洛尔静脉注射治疗急性冠脉综合征合并室性心律失常41例临床分析.临床医学研究与实践, 2016, 1(11):31.
[6]陶卫国,宋飞月,张高喜,等.美托洛尔对急性心肌梗死患者心功能和心率的影响.深圳中西医结合杂志, 2018, 28(7):160-161.
[7]王莉,陈静,贾艳梅,等.替格瑞洛联合阿司匹林治疗急性冠脉综合征的临床疗效及护理观察.中国医药导刊, 2014(8):1243-1244.
[8]孙美瑜.阿司匹林联合替格瑞洛治疗急性冠状动脉综合征的临床疗效观察.中国医药指南, 2018(8):32.
[9]劳国华,陈晓燕,黄子通.替格瑞洛联合阿司匹林治疗急性冠脉综合征的临床观察.岭南心血管病杂志, 2014, 20(3):317-318.
[10]潘迪,黄菲.替格瑞洛联合阿司匹林治疗急性冠脉综合征疗效观察.中国实用医药, 2016, 11(29):143-145.
[11]周金和.替格瑞洛联合波立维治疗急性冠状动脉综合征的临床疗效研究.川北医学院学报, 2018, 33(6):923-925.